Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 04, 2015 8:50 PM ET


Company Overview of AnaptysBio, Inc.

Company Overview

AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...

10421 Pacific Center Court

Suite 200

San Diego, CA 92121

United States

Founded in 2005





Key Executives for AnaptysBio, Inc.

Chief Executive Officer, President and Director
Executive Chair
Age: 50
Age: 52
Vice President of Finance and Controller
Chief Development Officer
Age: 58
Compensation as of Fiscal Year 2015.

AnaptysBio, Inc. Key Developments

AnaptysBio Announces Board Appointments

AnaptysBio, Inc. announced the appointment of Hollings Renton and John Schmid to its Board of Directors. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015.

AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Hamza Suria, Chief Executive Officer, President and Director.

AnaptysBio, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 12:40 PM

AnaptysBio, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 12:40 PM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director, Marco Londei, Chief Development Officer.

Similar Private Companies By Industry

Company Name Region
Toma Biosciences, Inc. United States
Chrono Therapeutics Inc. United States
Mytogen, Inc. United States
Molecular Templates, Inc. United States
Celera Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AnaptysBio, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at